Production and Immune Response Against Pandemic Influenza Candidate Vaccines as Preparedness Against the Circulating H5N1 Influenza Viruses

Author(s):Show less -

Lee Ho, Paulo ; Medina-Armenteros, Yordanka ; Mendonca Munhoz Dati, Livia ; Cajado-Carvalho, Daniela ; Savio Silva, Christian ; Fernandes Campos, Pollyanna ; Abreu, Patricia Antonia Estima ; Tavares de Castro, Julia ; Tonolli, Paulo Newton ; Fujimori, Mahyumi ; Silveira Martins Rosa, Rhubia ; Palameta, Soledad ; Edward Miller, Michael ; Sakihara, Vitor Anselmo ; de Lima Valadares, Fernanda ; Lauretti Ferreira, Fabiana ; Pereira Carvalho Holanda, Bianca ; Goncalves de Macedo, Douglas ; Comone, Priscila ; de Souza Suffert Fogaca, Natully ; Bimbo, Alexandre ; Catanzaro De Moraes, Felipe ; Queiroz de Andrade, Stephane Tereza ; Lage Ferreira, Helena ; Luiz Durigon, Edison ; Weis Arns, Clarice ; George Kallas, Esper ; Apetito Akamatsu, Milena ; das Neves Oliveira, Ricardo

• Document type: Journal article
• Source: VACCINES; v. 13, n. 6, p. 21-pg., 2025-06-08.

Abstract

Background/Objectives:H5N1 influenza viruses are spreading worldwide and threaten global public health. Preparedness is necessary to mitigate the worst-case scenario should an H5N1 influenza pandemic occur and justify the development of vaccines against circulating H5N1 viruses of concern. Methods: The production and characterization of egg-based split and inactivated H5Nx of three distinct monovalent antigens from clades 2.3.4.4b, 2.3.2.1c, and 2.3.4 were performed at an industrial scale. These antigens were formulated and their immune responses, when combined or not with IB160 squalene-based oil-in-water emulsion adjuvant in a rat model, were evaluated in a one- or two-dose immunization schedule. IgG antibodies, hemagglutination inhibitions, and microneutralization titers were measured for vaccine-induced immunity and cross-reactivity. Results: Three monovalent vaccines from clades 2.3.4.4b, 2.3.2.1c, and 2.3.4 were produced at an industrial scale and characterized. The immune responses against the monovalent vaccines showed a clade-specific antibody response and the need to combine with IB160 adjuvant for a required immune response. Conclusions: Considering the candidate vaccine viruses (CVVs) with the testing potency reagents available and that the antibody response obtained against the CVVs produced was clade-specific, IDCDC RG-71A is the indicated CVV for the predominant currently circulating H5N1 influenza virus of clade 2.3.4.4b and must be combined with adjuvant to induce a higher and efficacious immune response in a two-dose immunization protocol. (AU)

• FAPESP's process: 20/07040-1 - Center of Research and Development in Immunobiologicals
• Grantee: Ana Maria Moro
• Support Opportunities: Research Grants - Problem-Oriented Research Centers in São Paulo